Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Toxicity Conditioning for SAA Transplantation
NCT00882323Phase 2Unknown
- Sponsor
- Korean Society of Pediatric Hematology-Oncology
- Start
- Nov 2008
- Primary completion
- Oct 2012
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin, fludarabine and cyclophosphamide in aplastic anemia, sponsored by Korean Society of Pediatric Hematology-Oncology. Primary endpoint: Engraftment potential up to 4 years. Status: unknown.
02
Drugs
antithymocyte globulinfludarabinecyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT00882323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882323.